12:00 AM
Aug 17, 2009
 |  BC Week In Review  |  Clinical News  |  Regulatory

Saphris asenapine regulatory update

FDA approved an NDA from Schering-Plough for Saphris asenapine sublingual tablets for the acute treatment of schizophrenia and for acute treatment of manic or mixed episodes associated...

Read the full 115 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >